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Abstract 
 
Objective:  The mechanisms of action underlying treatment are inadequately understood. This 
study examined five variables implicated in the treatment of Panic Disorder with Agoraphobia 
(PD/AG): catastrophic agoraphobic cognitions, anxiety about bodily sensations, agoraphobic 
avoidance, anxiety sensitivity, and psychological flexibility. The relative importance of these 
process variables was examined across treatment phases: 1) psychoeducation/ interoceptive 
exposure; 2) in situ exposure; 3) generalization/ follow-up. 
Method: Data came from a randomized controlled trial of CBT for PD/AG (n=301). 
Outcomes were the Panic Agoraphobia Scale (PAS) and functioning as measured in the 
Clinical Global Impression (CGI). The effect of process variables on subsequent change in 
outcome variables was calculated using bivariate latent difference score modeling.  
Results: Change in panic symptomatology was preceded by catastrophic appraisal and 
agoraphobic avoidance across all phases of treatment; by anxiety sensitivity during 
generalization/ follow-up; and psychological flexibility during exposure in situ. Change in 
functioning was preceded by agoraphobic avoidance and psychological flexibility across all 
phases of treatment; fear of bodily symptoms during generalization/ follow-up; and anxiety 
sensitivity during exposure. 
Conclusions:  The effects of process variables on outcomes differ across treatment phases and 
outcomes (i.e., symptomatology vs. functioning). Agoraphobic avoidance and psychological 
flexibility should be investigated and therapeutically targeted in addition to cognitive 
variables.  
 
Keywords: Mechanism of Action, CBT, Panic Disorder, Agoraphobia, Avoidance, 
Psychological Flexibility 
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Timing Matters: Change Depends on the Stage of Treatment in Cognitive Behavioral Therapy 
for Panic Disorder with Agoraphobia 
 
The efficacy of Cognitive Behavioral Therapy (CBT) for Panic Disorder (PD) and 
Agoraphobia (AG) is undeniable, yet the crucial task of elucidating the mechanisms of action 
lags behind. Far from an abstract theoretical concern, understanding the mechanisms of action 
of treatment would provide knowledge on how to generalize the principles utilized in 
treatment studies and offer hope for the sizable minority of patients that do not respond to 
current treatments (Hofmann & Smits, 2008) by amplifying those specific processes known to 
affect outcome. Towards this aim, conceptual and methodological clarity are crucial.   
Much theoretical and empirical work has been devoted to explaining the nature and 
treatment of PD and AG. Cognitive accounts suggest that catastrophic misinterpretation of 
bodily sensations influences the etiology and maintenance of PD and AG (Clark, 1986).  
Cognitive therapy thus targets the content and frequency of associated thoughts through 
numerous methods. Anxiety Sensitivity, or the fear of anxiety and fear, has also been 
conceptualized as a risk factor associated with the subsequent onset of panic disorder (Ehlers, 
1995), and with avoidance behaviors (Zvolensky & Forsyth, 2002). Anxiety sensitivity is 
consequently considered an important therapeutic target for PD/AG (Smits, Powers, Cho, & 
Telch, 2004) achieved through various means including interoceptive exposure. However, the 
pernicious effects of both cognitive appraisals and anxiety sensitivity depend in part on how 
an individual attempts to regulate their negative affect (Kashdan, Zvolensky, McLeish, 2008). 
This suggests that successful therapy must also target the way one interacts with these 
negative appraisals, beliefs, and emotions.       
A common regulation strategy for these negative appraisals and emotions is 
avoidance. Indeed, agoraphobic avoidance, or the avoidance of feared situations, is a defining 
feature of agoraphobia (Chambless, Caputo, Jasin, Gracely, & Williams, 1985) even in the 
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absence of PD (Wittchen et al., 2008; Wittchen, Gloster, Beesdo-Baum, Fava, & Craske, 
2010). Although not always explicitly targeted (Hofmann & Spiegel, 1999), reduction of 
agoraphobic avoidance is a common therapeutic target and is associated with successful 
outcome (Gloster et al., 2011). Another regulatory strategy recently implicated in PD/AG is 
psychological flexibility. Psychological flexibility refers to the ability to mindfully accept 
cognitions and emotions when doing so is useful for living a meaningful life (Bond et al., 
2011). Similar to anxiety sensitivity, psychological flexibility is not exclusively relevant to 
PD/AG, yet has been implicated in panic-related distress (Karekla, Forsyth, & Kelly, 2004), 
baseline functioning in anxiety disorders (Gloster, Klotsche, Chaker, Hummel, & Hoyer, 
2011), treatment outcome (Forman, Herbert, Moitra, Yeomans, & Geller, 2007), and is 
conceptually distinct from anxiety sensitivity in patients with PD/AG (Kämpfe et al., 2012). 
Given that appraisal of anxiety symptoms, anxiety sensitivity, avoidance, and 
psychological flexibility are all associated with various aspects of PD/AG, it is important to 
understand to what degree some or all these constructs are active mechanisms for successful 
treatment outcome. Mediation analysis (Baron & Kenny, 1986) has emerged as one important 
analytical procedure for the critical testing of putative mechanisms of action in therapy 
(Kazdin, 2007) and a handful of formal mediation analyses have been conducted across 
variations of CBT for PD/AG (e.g., group vs. individual therapy). These studies provide 
positive evidence for the mediating or partially mediating role of cognitive content, cognitive 
appraisal, and self-efficacy (Casey, Newcombe, & Oei, 2005; Hofmann et al., 2007, 
Meulenbeek, Spinhoven, Smit, Van Balkom, & Cuijpers, 2010; Vögele et al., 2010) and 
anxiety sensitivity (Smits, Powers, Cho, & Telch, 2004) in reducing the severity of panic 
disorder. Although an important step towards isolating active mechanisms, these findings are 
limited by the fact that the assessment of target variables did not precede outcome 
assessments. That is, the process variables were tested concurrently with the outcome measure 
(e.g., both measured pre – post). This lack of temporal order hinders interpretation because it 
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is unclear if the outcome variables also influence the process variables and because such 
designs leave open the possibility that process variables exert their effects at different points 
during the therapy.  
Longitudinal temporal testing of putative mechanisms within the course of treatment 
for PD/AG has been examined only in a few studies. In one such study, 12 patients diagnosed 
with PD/AG completed daily diaries for 30 weeks (Bouchard et al., 2007). CBT was 
administered in groups and emphasized either cognitive or exposure interventions. Daily 
dairies were used to assess beliefs about the consequences of panic, self-efficacy to control 
panic attacks in the face of bodily sensations and catastrophic thoughts, and anticipatory 
anxiety about having a panic attack that day. During the course of therapy, all 12 patients 
recorded changes in their beliefs and level of self-efficacy prior to recording changes in 
anticipatory anxiety, irrespective of condition.  Despite the small sample size, this study 
demonstrated with temporal sensitivity that changes in cognitive variables preceded change in 
other aspects of symptomatology for all patients, though the magnitude of change differed 
across patients.  
To our knowledge, only a few further studies temporally examined whether salient 
process variables preceded subsequent change in panic-related outcomes. Using cognitive 
therapy and guided mastery – both administered in a group format – Hoffart (1995) examined 
the relevance of self-efficacy, catastrophic beliefs, and perceived control of thoughts on 
subsequent fear in a behavioral avoidance test (BAT). Results from the 46 patients included in 
the study indicated that change in self-efficacy was the strongest and most consistent 
predictor of subsequent change in fear during the BAT. A second study (Teachman, Marker, 
& Clerkin, 2010) examined whether catastrophic misinterpretations subsequently affected 
various facets of panic symptomatology. Panic control treatment was administered in a group 
format to 43 patients. Using bivariate difference score modeling analysis, results indicated 
that change in catastrophic misinterpretation predicted subsequent change in panic 
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symptomatology. The reverse pattern (i.e., symptomatology predicting subsequent change in 
catastrophic misinterpretation) was not consistently found except for distress/ apprehension. 
A final study examined cognitive process variables during the first phase of treatment (i.e., 
four weeks) in 41 patients diagnosed with PD/AG (Meuret, Rosenfield, Seidel, Bhaskara, & 
Hofmann, 2010) across two distinct treatment conditions. Process variables were 
operationalized as a composite score of questionnaires that measure anxiety sensitivity/ fear 
about the consequences of panic (i.e., anxiety sensitivity index (ASI) and body sensation 
questionnaire (BSQ), respectively) in addition to perceived control. During the phase of 
treatment examined, patients received either cognitive treatment or capnometry-assisted 
respiratory training.  So designed, the specificity of the cognitive process variables could be 
tested across relatively pure intervention conditions. Indeed, results suggested that cognitions 
were bidirectionally associated with changes in panic severity only in the cognitive training 
condition whereas perceived control was bidirectionally associated with panic symptom 
change in both conditions. This excellent study included information only from the first half 
of treatment (four weeks), however, thus limiting information about how mechanisms unfold 
over the full course of treatment or generalize following treatment. Taken together, these 
studies provide strong support for the role of cognitively oriented process variables defined as 
catastrophic misinterpretations and self-efficacy in the prediction of subsequent change in 
symptomatology. 
To our knowledge, no other PD/AG relevant process variables than those discussed 
above (i.e., feared consequences / anxiety sensitivity and self-efficacy/ perceived control to 
cope with panic) have been tested. Examination and direct comparison of other variables 
implicated in the treatment of PD/AG such as avoidance behavior and psychological 
flexibility is a crucial step in the process of understanding the mechanisms of treatment 
(Kazdin, 2007).   
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In addition to expanding the scope of process variables under investigation, outcome 
variables also need to be expanded. To date, all process studies examined the effect on panic-
related variables, but only one examined how putative mechanims affect other outcomes such 
as functioning (Smits et al., 2004). It remains an open question whether the mechanisms of 
action involved in symptom reduction are identical in importance and sequence to those 
involved in other treatment targets. Social, occupational, and psychological functioning are 
certainly related to symptomatology, yet it is a broader measuring stick. Indeed, the impetus 
for patients to seek therapy may be primarily related to functioning and in our quest to better 
understand mechanisms care should be taken not to reduce patients to their symptomatology.  
This purpose of the present study was to investigate the degree to which five process 
variables affect treatment outcome across the active and follow-up phases of a standardized 
CBT for PD/AG. Towards this end, the process variables were examined across phases of 
therapy for two outcomes: severity of PD/AG symptomatology and overall functioning. The 
process variables were examined longitudinally using bivariate latent difference score 
modeling to determine the relative effects of the process variables at different points in the 
therapeutic process.  So doing, the relative importance of the process variables were examined 
for their relationship to different components of the therapy. We hypothesized that the 
variables would differentially predict subsequent symptoms as a function of treatment phase 
(i.e., psychoeducation, functional analysis, interoceptive exposure [pre-treatment to 
intermediate assessment following the 4th session]; exposure in situ, anticipatory anxiety and 
specified interoceptive exposure [intermediate assessment to post-treatment following the 12th 
session]; and generalization period with two booster sessions that reviewed progress, helped 
set goals, and addressed difficulties [post-treatment to 6-month follow-up period]) and 
outcome variable (panic and agoraphobia symptoms vs. functioning). Specifically, we 
predicted that a) cognitive appraisal would predict subsequent change in panic symptoms, but 
not functioning, only during sessions 1-4 because these sessions addressed psychoeducation 
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and engaged the patient intellectually; b) anxiety elicited by bodily symptoms would predict 
subsequent change in panic symptom, but not functioning, only during sessions 1-4 because 
these sessions introduced interoceptive exposure; c) anxiety sensitivity would predict 
subsequent change panic symptoms during sessions 1-12 because of interoceptive exposure 
during the first 4 sessions and exposure in situ during 2nd half of treatment and functioning 
during treatment because improvement in function is likely related to a new relationship with 
the anxiety; d) avoidance behavior would predict subsequent change in both panic symptoms 
and functioning across sessions 1-12 and the follow-up period because avoidance was directly 
and intensively targeted in the therapy as a maintaining factor, and e) and psychological 
flexibility would predict subsequent change in panic symptoms during sessions 5-12 because 
it is believed to facilitate exposure and functioning during all phases because it is closely tied 
to functioning.  
Methods 
Design  
Data were collected within the Mechanisms of Action for CBT (MAC) study. The 
MAC study was a multicenter, randomized controlled trial for patients with PD/AG. The 
methods and main outcomes of the study were published elsewhere (Gloster et al., 2009; 
Gloster et al., 2011). The MAC study was approved by the internal review board of all 
relevant institutions. The current study included all patients (n =369), but the longitudinal 
analyses were limited only to those patients who received treatment (n = 301). Thus, the n = 
68 waitlist patients were excluded from this set of analyses.  
Participants  
All patients met Diagnostic and Statistical Manual of Mental Disorders (4th ed., text 
rev.; DSM-IV-TR; American Psychiatric Association, 2000) diagnostic criteria for PD with 
AG, scored ≥18 on the Hamilton Anxiety Scale (HAM-A), and ≥4 on the Clinical Global 
Impression Scale (CGI). Other current comorbid diagnoses, including unipolar depression and 
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other anxiety disorders, were allowed unless they were of primary clinical concern. Over 90% 
of the sample had at least one comorbid condition, with nearly half the sample diagnosed with 
two or more mental disorders in addition to PD/AG. The most frequent comorbid conditions 
were specific phobia (n = 214; 71.1%), harmful use/abuse of alcohol (n = 135; 44.9%), social 
phobia (n = 126; 42.4%), and major depression (n = 118; 39.2%). As such, this sample can be 
considered both relatively severe and representative of patients seen in clinical practice. All 
patients were free from psychopharmacological medication. Extensive details about inclusion 
and exclusion criteria have been previously published (Gloster et al., 2009; Gloster et al., 
2011).  
The 301 patients in this study had a mean age of 35.5 (10.7). A majority of patients 
were women (n = 228, 75.8%) and 131 (43.5%) had at least some higher education. Nearly a 
third were married (n = 98, 32.7%), half were single (n = 165, 55.0%), and the rest were 
divorced or widowed. Consistent with the demographic characteristics of the population from 
which these data were sampled, all participants were of Caucasian origin.      
Treatment 
Patients received a 12-session manualized treatment protocol (Lang, Helbig-Lang, 
Westphal, Gloster, & Wittchen, 2011), implemented over 6 weeks, and followed by two 
booster sessions. Sixty-three certified therapists, all of whom were either advanced graduate 
students or post-docs, administered treatment. All therapists went through a thorough training 
and certification procedure. Treatment integrity, training, randomization, and further design 
issues are published elsewhere (Gloster et al., 2011). 
The treatment was highly efficacious (Gloster et al., 2011) and consisted of three 
phases: 1) psychoeducation, individualized behavioral analysis, rationale for exposure, 
interoceptive exposure exercises (sessions 1-4); 2) standardized in-situ exposure exercises, 
anticipatory anxiety, individualized in situ exposure exercises (sessions 5-12); and 3) the 
generalization period through the 6-month follow-up assessment. The study had two active 
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treatment groups that varied only with respect to the implementation of a single component 
(in situ exposure with [T+] vs. without [T-] the therapist present), but not content. No 
relaxation exercises, breathing retraining, or explicit logical empiricism and disconfirmation 
of thoughts were undertaken in either group. 
Assessment 
Measures were assessed pre-treatment, at the intermediate point in treatment (between 
the 4th and 5th sessions), post-treatment (after the 12th session), and at the 6-month follow-up, 
which occurred 6 months after the post-treatment assessment. The one exception is the 
anxiety sensitivity index, which was not measured at the intermediate assessment.  
PD/AG symptomatology and clinical functioning. 
Panic and Agoraphobia Scale (PAS; Bandelow, 1997). The PAS is a patient self-
report, 13-item questionnaire that measures the severity of panic attacks, avoidance, 
anticipatory anxiety, disability, and worries about health.  All items are scored from 0 to 4. 
Scores on the PAS have have good reliability and are sensitive to change (Bandelow, 1997; 
Gloster et al., 2011). The internal consistency of the PAS in this sample was α = 0.86. 
Clinical Global Impression Scale – Severity Subscale – Functioning Item (CGI; 
Guy, 1976). CGI is a clinician-rated scale that measures the overall severity of a disorder, 
with scores that range between 1 (no disorder) and 7 (among the most severely ill patients). 
The scale normally queries for information across the facets of panic symptoms, anxiety, 
anticipatory anxiety, avoidance, and overall functional level before making the global rating. 
Scores on the CGI are sensitive to change in panic treatment (Barlow et al., 2000; Gloster et 
al., 2011). For this study we only used the one item measuring overall functioning in order to 
maximize conceptual distinctness from the PAS.  
 Process Variables.  
Agoraphobic Cognitions Questionnaire (ACQ; Chambless, Caputo, Bright, & 
Gallagher, 1984). The ACQ is a 14-item self-report questionnaire that measures the 
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frequency of catastrophic beliefs about the possible consequences of experienced anxiety and 
panic. Each item is rated on a five-point scale, ranging from 1 (never) to 5 (always). The ACQ 
has sound psychometrics and is a standard assessment in PD/AG research (Zgourides, 
Warren, & Englert, 1989). The internal consistency of the ACQ in this sample was α = 0.74. 
Bodily Sensations Questionnaire (BSQ; Chambless et al., 1984).The BSQ is a 17 
item self-report questionnaire that measures the degree of anxiety elicited by body sensations. 
Each item is rated on a five-point scale, ranging from 1 (not at all) to 5 (extremely). The BSQ 
has sound psychometrics and is a standard assessment in PD/AG research (Zgourides, 
Warren, & Englert, 1989). The internal consistency of the BSQ in this sample was α = 0.87. 
Mobility Inventory (MI; Chambless, Caputo, Jasin, Gracely, & Williams, 1985). The 
MI is a self-report questionnaire that measures the degree to which 27 situations are avoided. 
Items are scored from 1 (never avoid the situation) to 5 (always avoid the situation), with the 
mean of all items as the total score.  Scores of the MI are highly reliable and sensitive to 
change (Chambless et al., 1985; Gloster et al., 2011).  For this study, only the ratings for the 
“alone” subscale are utilized. The internal consistency of the MI in this sample was α = 0.93. 
Anxiety Sensitivity Inventory (ASI; Peterson & Reiss, 1993). The ASI is a 16-item 
self-report questionnaire that measures beliefs about potential harmful consequences of 
anxiety related symptoms. Each item is rated on a five-point scale from 0 (very little) to 4 
(very much). The ASI has demonstrated sound psychometrics and is associated with various 
indices of PD/AG and other anxiety disorders (Rodriguez, Bruce, Pagano, Spencer, & Keller, 
2004). The internal consistency of the ASI in this sample was α = 0.86. 
Acceptance and Action Questionnaire – II (AAQ-II;Bond et al., in press). The AAQ-
II is a 7-item self-report questionnaire that measures psychological flexibility. Each item 
is rated on a seven-point scale from 1 (never true) to 7 (always true). The AAQ-II has 
demonstrated sound psychometrics and is associated with various indices of PD/AG and other 
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anxiety disorders, with good discriminant validity (Bond et al, 2011; Gloster et al., 2011).  
The internal consistency of the AAQ-II in this sample was α = 0.94. 
Statistical Analyses  
 
Lower level mediation analyses were conducted to investigate the association of the 
five process variables ACQ, BSQ, MI, ASI, AAQ-II and the change in treatment outcomes 
PAS and CGI over time (Kenny, Korchmaros, & Bolger, 2003) as a preliminary step in data 
analyses. The associations were estimated by Multilevel linear mixed models with time as 
predictor variable, the five process variables ACQ, BSQ, MI, ASI and AAQ-II as time 
varying covariates and PAS and CGI as outcomes (Kenny, Korchmaros, & Bolger, 2003; 
Singer & Willet, 2003). 
Latent difference score (LDS) models provide a tool where change and individual 
differences in change are represented in the model (Selig & Preacher, 2009). LDS 
incorporates features of latent growth curve modeling and cross-lagged regression models. 
We only shortly describe our analytic strategy, a detailed presentation of the theory can be 
found in McArdle & Nesselroade (1994) or Hawley, Ho, Zuroff & Blatt (2006). We evaluated 
different univariate LDS models for the change of PAS, CGI, ACQ, BSQ, ASI, AAG-II and 
MI over time for investigating the nature of change in a first step. The latent change in a 
repeatedly observed score Y in an individual n at time t can be expressed by 
Δ y(t)n = y(t)n - y(t-1)n = αy syn + βy y(t-1)n, 1 
where the observed score Y(t)n can be decomposed into a true score y(t)n and a measurement 
error  en with a mean of zero and a positive variance. The latent change in Y is the sum of two 
components in equation (1), an additive (αn syn) and a proportional (βy y(t-1)n) change 
component. The coefficient syn corresponds to an intercept in the equation, which may vary 
across individuals and is constant over time. The α coefficient is a factor loading and fixed to 
one for model identification purposes. The coefficient βy represents the proportional effect of 
the previous latent variable on the change rate. We compared univariate LDS models for time-
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invariant and time-varying proportional coefficients βy as well as a no change score LDS 
model (Δ y(t)n = 0, αy = βy = 0 in equation 1) for each considered score. The univariate LDS 
models where combined to establish bivariate LDS in a second step. Bivariate LDS models 
provide an appealing feature for investigating whether one score is the leading indicator of 
change in the other variable. A coupling parameter γ is included into the equations of two 
univariate LDS models representing the effect of one score on the rate of change in the other. 
The bivariate LDS model with an other score z(t) at time t can be written by 
Δ y(t)n = y(t)n - y(t-1)n = αy syn + βy y(t-1)n + γz z(t-1)n 
Δ z(t)n = z(t)n - z(t-1)n = αz szn + βz z(t-1)n + γy y(t-1)n. 
2 
The relationship between the two dual change LDS models is given by the components γz z(t-
1)n and γy y(t-1)n besides the additive and proportional change components. The subsequent 
latent change in one variable is predicted by the other variable occuring earlier in time in case 
of coupling between the two univariate LDS models. We investigated different patterns of 
coupling between two univariate LDS models by restricting the path coefficients in the 
models. The analyses included models with (i) no coupling (γz = 0 and γy = 0) between the two 
series, (ii) unidirectional coupling exists in which one variables predicts later change in the 
other and vice versa (γz = 0 and γy ≠ 0 or γz ≠ 0 and γy = 0) and (iii) bidirectional coupling 
exists between the two scores (γz ≠ 0 and γy ≠ 0). We also compared models with time-
invariant and time-varying coupling coefficients γz and γy. Whenever the final model indicated 
that more than one γ coefficent (one per phase of treatment) per process variable was 
significant, the ceofficencts were tested for significant differences. The third step of our 
analyses concerns the hypotheses whether treatment condition (T+ vs. T-) predicts the 
subsequent rate of change in the studied variables over the treatment process. Treatment 
condition is added by the term (φ TX) in the equations 2. All path coefficients are reported as 
unstandardized coefficients.  The parameters of the LDS models were estimated in Mplus 
version 6.1 (Muthen & Muthen, 2007). We used the full the full-information maximum 
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likelihood estimator due to missing data in some cases. This approach ensures the use of all 
available data for parameter estimation. Thus, also patients with incomplete sessions were 
incorporated into analyses. 
Results 
Baseline Values 
 The mean and standard deviations for the outcome variables and process variables at 
baseline and post-treatment are displayed in Table 1.  The correlations between variables at 
baseline and post-treatment are likewise displayed in Table 1. 
Lower level mediation models 
The association of the five process variables ACQ, BSQ, ASI, MI, AAQ-II and the 
treatment outcomes PAS and CGI were investigated by lower level mediation models. This 
preliminary step was conducted in view of the existing literature. ACQ, BSQ, MI, ASI and 
AAQ-II all partially mediated the treatment outcomes of PAS and CGI as indicated by a 
significant mediated effect in the mediator analyses (available upon request). However, lower 
level mediation models are inadequate to show sequencing across time.  
The WL reported only negligible pre-treatment to post-treatment changes and was 
significantly worse than both treatment groups at post-treatment (see Gloster et al., 2011). 
Nevertheless, the WL was tested here using lower-level models. As expected, the WL group 
did not demonstrate any meditational effects. As no meaningful change was observed in this 
group, predicting change was not possible and this group was excluded from further 
longitudinal analyses below.  
Univariate Latent Difference Score Models 
The change in PAS, CGI, ACQ, BSQ, MI, ASI and AAQ-II was investigated by 
univariate LDS models including the no change model and the two dual change models with 
both time-varying and time-invariant proportional effects β(t). The no change LDS models 
consistently resulted in a poor model fit (SRMR ranges form .26 for ASI to .42 for AAQ-II). 
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The univariate LDS models including time-varying proportional effects β(t) substantially 
improved model fit compared to time-invariant proportional effects in all analyzed models. 
The model fit of the univariate LDS models can be considered to be acceptable for modeling 
the change in the seven variables over time by a dual change model with time-varying 
proportional effects (CFI ranges from .86 for CGI to .98 for ASI; TLI ranges from .84 for MI 
to .98 for AAQ-II; RMSEA ranges from .08 for AAQ-II and MI to .14 for CGI; SRMR ranges 
from .04 for ASI to .10 for MI). Unstandardized parameter estimates for the proportional 
effects β(t) were statistically significant (ps ranging from <.001 to .043) except for the BSQ 
and MI. The latent BSQ (β1 =-.12, p=.35) and MI (β1=-.15, p=.10) at baseline assessment did 
not significantly predict the subsequent rate of change. Detailed information is reported in 
table 2 about model fit and parameter estimates for the additive additive and proportional 
change components. 
Bivariate Latent Difference Score Models 
The parameter estimates and the model fit indices are reported in table 3 for the final 
bivariate LDS models. The final models were selected based on considering a combination of 
the Bayesian information criterion (BIC), the comparative fit index (CFI), the Tucker-Lewis 
index (TLI), root-mean-square error of approximation (RMSEA) and standardized root mean 
square residual (SRMR). 
Panic and agoraphobia symptoms. Five bivariate LDS models were conducted for 
evaluating the coupling between the univariate series of PAS and ACQ, BSQ, ASI, MI and 
AAQ-II. We compared four models for each variable combination, where (i) no coupling 
exists, (ii) unidirectional coupling from PAS to the process variable, (iii) unidirectional 
coupling from the process variable to PAS and (iv) bidirectional coupling between PAS and 
process variable. Given our results, the bivariate LDS models including unidirectional 
coupling from ACQ to PAS (SRMR=.05), BSQ to PAS (SRMR=.06) and ASI to PAS 
(SRMR=.03) resulted in best model fit. Latent ACQ significantly predicts later change in PAS 
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for baseline to intermediate (γ1,ACQ_PAS), intermediate to post (γ2, ACQ_PAS) and post to follow-up 
(γ3, ACQ_PAS) assessment. The coupling coefficient γ2, ACQ_PAS significantly differs from γ3, 
ACQ_PAS (χ2(1)=12.78, p<.001), indicating that the strongest association existed for latent ACQ 
predicts change in PAS at the interval post to follow-up assessment. Latent BSQ did not 
predict later change in PAS over time. Latent ASI at post assessment predicted later change in 
PAS (γ3, ASI_PAS=.28, p=.02). The longitudinal association of PAS and MI was best modeled by 
a bivariate LDS model with time-invariant coupling coefficients (SRMR=.06). Latent MI 
predicted later change in PAS (γ1,MI_PAS = γ2, MI_PAS = γ3, MI_PAS=11.0, p<.001), suggesting the 
effect of MI was not different across treatment phases. Notably, latent PAS also predicted 
later change in MI (γ1,PAS_MI = γ2, PAS_MI = γ3, PAS_MI = .13, p<.001). The bivariate LDS model 
with bidirectional coupling and time-varying coupling coefficients for PAS and AAQ-II 
achieved best model fit (SRMR=.04). Latent AAQ-II predicted later change in PAS in the 
interval intermediate assessment and post assessment (γ3, AAQ-II_PAS=.13, p=.03). 
Clinical Functioning. Bivariate LDS models were applied for investigating the 
associations of CGI and the five process variables over time. The final models included 
bidirectional coupling coefficients. The alternative bivariate LDS models for CGI and ACQ 
including no coupling, unidirectional coupling and bidirectional coupling resulted in an 
acceptable (RMSEA ranges from .12 to .13, SRMR ranges from .17 to .18, CFI is .9, TLI 
ranges from .81 to .85). The LDS model for CGI and ACQ with the closest fit included 
coupling coefficients that were constraint to be equal over time. Neither latent ACQ nor CGI 
predicted later latent change in the other variable. Latent BSQ at post assessment significantly 
predicted later change in CGI (γ3,BSQ_CGI=.20, p=.03). In contrast, change in CGI did not 
predict later change in BSQ. The best fitting bivariate LDS model for ASI and CGI 
(SRMR=.04) included bidirectional time-varying coupling coefficients for ASI predicting 
later change in CGI and time-invariant coupling for CGI predicting later change in ASI. 
Latent ASI at post assessment predicted later change in CGI (γ2,ASI_CGI=.06, p<.001). Notably, 
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change in CGI significantly predicted later change in ASI over time (γ1,CGI_ASI = γ2, CGI_ASI = γ3, 
CGI_ASI = 5.79, p<.001). The longitudinal association of CGI and MI was best modeled by a 
bivariate LDS model with time-invariant coupling coefficients (SRMR=.18), suggesting the 
effect of MI is not significantly different across treatment phases. It is notable that even the 
best fitting model did not result in a consistent good model fit. The indices CFI (CFI = .90) 
and TLI (TLI = .85) suggested an acceptable model fit, whereas RMSEA (RMSEA = .14) and 
SRMR (SRMR = .18) suggested a poor model fit. Latent MI predicted later change in CGI 
(γ1,MI_CGI = γ2, MI_CGI = γ3, MI_CGI=2.58, p<.001) and latent CGI also predicted later change in 
MI (γ1,CGI_MI = γ2, CGI_MI = γ3, CGI_MI = .96, p<.001). The bivariate LDS model for AAQ-II and 
CGI including time-varying coupling coefficients resulted in an acceptable model fit 
(SRMR=.09). Latent AAQ-II predicted later change in CGI over time (γ1,AAQ-II_CGI = .40, 
p=.008; γ2, AAQ-II_CGI = .43, p=.01; γ3, AAQ-II_CGI=.47, p<.014) and vice versa (γ1,CGI_AAQ-II = 9.4, 
p=.004; γ2, CGI_AAQ-II = 8.5, p=.011; γ3, CGI_AAQ-II= 6.1, p=.028). Although the three coupling 
coefficients for latent AAQ-II predicting later change in CGI differed, these differences were 
not significantly different throughout treatment. 
Treatment condition. We tested whether the treatment condition in our study (T+ vs. 
T-) predicted the rate of change in outcome and process variables. We added treatment 
condition to the best fitting bivariate LDS model as presented in table 3. For example, 
treatment condition was established as a predictor for the rate of change in ACQ in the 
bivariate LDS model for ACQ and PAS with unidirectional coupling (latent ACQ predicts 
later change in PAS). The goodness-of-fit parameters indicate a good model fit (χ2(23)=41.2, 
p=.01; CFI = .98; TLI = .97; RMSEA = .05; SRMR = .05). However, treatment condition did 
not significantly predict change in ACQ throughout treatment (φ1 = -.02, p=.88; φ2 =.21, 
p=.79; φ3 = 1.60, p=.07). A similar pattern was found for the other biavariate LDS models 
with treatment condition as an additional explanatory variable. 
Discussion 
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This study examined the mechanism of action in CBT for Panic Disorder with 
Agoraphobia using temporally sensitive bivariate latent difference score modeling in a large 
sample of 301 patients. Importantly, the current study found evidence for the temporal 
specificity of process-outcome effects over the course of therapy and differences between 
outcome measures. Change in a comprehensive measure of panic and agoraphobic symptoms 
(PAS) was consistently predicted across all phases of treatment by previous values of 
catastrophic appraisal (ACQ) and agoraphobic avoidance (MI). In contrast to the 
unidirectional relationship from ACQ to subsequent scores on the PAS, the relation between 
MI and PAS was bidirectional (i.e., scores on the PAS also predicted subsequent change on 
the MI). During the second phase of treatment (i.e., exposure in situ), scores on psychological 
flexibility (AAQ-II) predicted subsequent change in the PAS at post-treatment. This suggests 
that psychological flexibility is particularly relevant during the phase of treatment that 
patients are asked to face their fears. Further changes on the PAS during the 6-month follow-
up period were unidirectionally associated with scores on the ASI at post-treatment. Fear of 
bodily symptoms (BSQ) did not predict subsequent change in the PAS during any stage of 
therapy.  
Change in global functioning (CGI) presented a somewhat different picture. Scores in 
both agoraphobic avoidance (MI) and psychological flexibility (AAQ-II) predicted 
subsequent change in functioning across all phases of treatment. Likewise, scores on the CGI 
predicted subsequent changes in the MI and AAQ-II during these phases (bidirectional 
relations). This suggests that both avoidance and psychological flexibility are strongly related 
to functioning across the therapy and follow-up periods and are complexly intertwined with 
functioning. In addition, scores on anxiety sensitivity (ASI) at baseline predicted subsequent 
change in functioning from pre-treatment to post-treatment, as did functioning predict 
subsequent change in anxiety sensitivity (bi-directional relation). These bi-directional 
relationships may be similar to those observed by Teachman, Marker, & Clerkin (2010) with 
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the variables distress/ apprehension.  The only unidirectional relation with functioning was 
observed for scores on the fear of bodily symptoms (BSQ) at post-treatment for subsequent 
change in functioning between post-treatment and follow-up. Catastrophic appraisal (ACQ) 
did not predict subsequent change in functioning at any point during the study.  
Taken together, our hypotheses were partially supported. In partial contrast to our 
hypothesis, cognitive appraisal predicted subsequent change in panic and agoraphobia 
symptoms across all time points and not just during sessions 1-4. Consistent with our 
hypothesis, cognitive appraisal did not predict subsequent change in functioning. Contrary to 
our hypothesis, anxiety elicited by bodily symptoms did not predict subsequent change in 
panic symptoms at any time point and did predict subsequent functioning at the follow up 
assessment. Contrary to our hypothesis, anxiety sensitivity predicted subsequent panic and 
agoraphobia symptoms only during the follow-up period. However, consistent with our 
hypothesis, anxiety sensitivity was related to functioning during the treatment phase. 
Consistent with our hypotheses, avoidance behavior was related to subsequent change in 
panic symptoms and functioning across all phases. Also consistent with our hypothesis, 
psychological flexibility predicted subsequent change in panic symptoms during sessions 5-12 
and functioning across all time points.  
This research builds on previous studies, all of which used panic and/ or agoraphobic 
symptoms as an outcome variable. Although some of these studies largely lacked prospective 
temporal designs that measured process variables and outcome measures longitudinally (see 
Meuret et al., 2010, Teachman  et al., 2010 for exceptions), results from these studies help 
piece together the puzzle of the processes relevant for effective treatment. Indeed, our results 
are consistent with the reliable finding that measures of one’s appraisal of symptoms (e.g., 
ACQ, BSQ, and ASI) mediated or partially mediated outcome (Casey et al., 2005; Smits et 
al., 2004; Meuret et al., 2010; Hofmann et al., 2007; Voegele et al., 2010; Meulenbeek et al., 
2010).  This finding was also found in studies that used different analytical frameworks such 
TIMING MATTERS 
 
21 
 
as time series analysis (Bouchard et al., 2007) structural equation modeling (Hoffart, Sexton, 
Hedley, & Martinsen, 2008), and bivariate latent difference score modeling (Teachman, 
Marker, & Clerkin, 2010). 
The longitudinal analysis used in the current study advance our understanding of when 
and to some degree how the consistent finding that one’s appraisals of panic and agoraphobic 
symptoms mediates outcome. Consistent with previous studies, results of the current study 
suggest that panic symptomatology is affected by one’s catastrophic beliefs (ACQ) during all 
phases of treatment. These analyses also suggest that this effect is strongest during the 
generalization phase. Similarly, agoraphobic avoidance is associated with subsequent change 
in PAS across treatment. Interestingly, psychological flexibility seems to affect panic 
symptomatology during the in situ exposure phase of treatment. This would suggest that 
exposure in situ requires a patient to engage with the feared stimuli in a flexible manner and 
take steps to reduce avoidance behavior (see Gloster et al., 2012). During the follow-up 
period, agoraphobic avoidance, catastrophic cognitions, and fear of fear are the salient process 
variables. In sum, whereas cognitive variables do affect panic and agoraphobic-related 
outcome, the present results suggest that not all cognitive variables predict outcome, and 
which cognitive variables are the most salient predictors depends on the phase of treatment. 
However, given their exploratory nature these findings clearly require replication before firm 
conclusions can be drawn.  
We also found evidence for the process of change in two variables not previously 
tested. First, the degree of self-reported situational agoraphobic avoidance (MI) was most 
consistently associated with the reduction in panic and agoraphobic symptoms and 
functioning. The bidirectional relation suggests a complex relation between these variables, 
likely due in part to a partial overlap of the constructs. It is important to note that two 
previous mediation studies included agoraphobic avoidance in their analyses but treated it as a 
dependent variable (Vögele et al, 2010; Meulenbeek et al., 2010). We treated agoraphobic 
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avoidance as a potential process variable, however, because the treatment conceptualized 
avoidance and safety behaviors as a maintaining variable and directly targeted them (both 
those publically observable and those only observable to the patient). As such, the mobility 
inventory captured one class of this behavior. The final process variable associated with 
changes in the outcome was psychological flexibility (AAQ-II). This variable is not specific 
to panic and agoraphobia and the AAQ-II does not contain any words specifically referring to 
panic or agoraphobia. Instead, it is a broader construct that measures the degree to which one 
can mindfully accept thoughts and emotions while engaging in one’s life when it is important 
to do so. As such, it is theoretically consistent that psychological flexibility was associated 
with change in panic and agoraphobia symptoms only during the phase of treatment that 
concentrated on exposure in situ but not the phase that concentrated on psychoeducation 
(Gloster, Hummel, Lydmirskya, Hauke, & Sonntag, 2012): dropping subtle avoidance 
behaviors and mindfully accepting associated thoughts and emotions promotes change. It is 
likewise theoretically consistent that psychological flexibility was consistently related to 
subsequent change in functioning: promotion of psychological flexibility increases one’s 
ability to engage with that which is important to the patient.  
This study also expanded the examination of process variables on the outcome of 
global functioning. In addition to adding information about how the putative process variables 
affect a broader target, testing the process variables against the CGI also served as a test of 
specificity for the process variables. The variables associated with the change in global 
functioning were agoraphobic avoidance and psychological flexibility across all treatment 
phases; anxiety sensitivity during the active phase of treatment; and fear of bodily symptoms 
during the generalization phase of treatment. Interestingly, the cognitive appraisal process 
variables that have consistently been found to be associated with change in panic and 
agoraphobic symptoms were no longer significantly related to global functioning in the 
longitudinal models and only anxiety sensitivity was related to change in functioning during 
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the active treatment phase. This, therefore, partially supports and is simultaneously in partial 
contrast to Smits et al., 2004, who found that anxiety sensitivity statistically mediated 
functioning in a cross-sectional analysis. Differences may have resulted from the timing of 
measurements (concurrent measurement at pre and post vs. longitudinal), measurement 
format (clinician judgment in the present study versus questionnaire in Smits et al., 2004), 
differences in the treatment, or a combination of these factors.  Once again, there is a critical 
need for replications before the processes that lead to change in global functioning can be 
established. Results clearly point to crucial importance of testing across various definitions of 
outcome and especially of expanding beyond purely symptom-based definitions. If replicated, 
these results suggest that different processes are involved in the change of symptomatology 
and functioning across the various treatment phases.  
Treatment group (T+ vs. T-) did not contribute to the explanation of relation between 
processes and outcome and were not included in the final models. This suggests that despite 
the slight advantage seen by the T+ group in outcome (Gloster et al., 2001), both treatment 
variants seem to work through the same processes. This is not surprising as both treatment 
variants had identical content and differed only with respect to the therapist’s presence during 
exposure in situ. It remains a possibility that the presence of the therapist may have facilitated 
the dropping of safety behaviors or offered more intense guidance, but the sum total of such 
effects – if they do indeed exist – are not strong enough to be detected by these analyses.    
By linking process-outcome effects with specific phases and elements of treatment, we 
are in a stronger position to tie together results from outcome trials with current theories about 
the mechanisms that underlie treatment. For example, inhibitory learning that promotes 
tolerance of anxiety and develops competing non-threat expectancies and that can be 
generalized across contexts is believed to be a crucial mechanism in exposure therapy (Arch 
& Craske, 2008). This study, then, shows with temporal fidelity that some of the therapeutic 
techniques and processes are involved at different time points during the therapy and may 
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point to a specification of what is involved in the processes of inhibitory learning. That is, 
during the intensive exposure in situ phase of treatment, cognitive attribution, agoraphobic 
avoidance and psychological flexibility are associated with changes in PD/AG severity 
whereas changes in global functioning are associated with agoraphobic avoidance, 
psychological flexibility, and anxiety sensitivity. Although clearly in need of replication in 
other variations of CBT for PD/AG, this type of analysis aids in the understanding of 
treatment processes at specific level.  
 This study needs to be interpreted in the light of several limitations. First, although 
consistent with previous studies, the process variables examined in this study were assessed 
using questionnaires are limited by the retrospective recall bias inherent in questionnaires. 
Future studies using additional methodologies (e.g., ecological momentary assessment, 
physiological variables, etc.; e.g., Domschke et al., 2010; Kircher et al., in press; Richter et 
al., in press), with different sources of method variance are clearly needed. Second, although 
we broke down the effects of time across our treatment, the effects of time and the treatment 
components that occurred during that period of the treatment cannot be parceled apart. Third, 
the ASI was not administered during the intermediate assessment. Further, the original ASI 
was utilized in this study. Subsequent versions of the ASI have expanded the measure and 
emphasized its multidimensional aspects (Taylor & Cox, 1998; Taylor et al., 2007). Although 
all versions of the ASI target the overarching concept of anxiety sensitivity, results from this 
study do not inform about dimensions of anxiety sensitivity as accentuated in more recent 
versions of the ASI. Likewise, these results cannot speak to the taxonic structure of the ASI. 
Fourth, although agoraphobic avoidance was revealed to be of core relevance in these 
analyses, other subtle aspects of avoidance such as cognitive avoidance, utilization of safety 
signals, etc. were not specifically assessed and therefore the relevance of these and other 
unassessed factors could not be modeled.  Fifth, the examined process variables as well as the 
outcome variables are not without overlap. Whereas this not unique to this study, construct 
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overlap is extremely difficult to avoid in psychological research. To test the robustness of 
these results, we modeled several variations (i.e., with and without inclusion of the avoidance 
subscale on the PAS) and did not find any noticeable affect on the pattern of results.  Sixth, it 
should be noted that not even sophisticated statistical analyses such as bivariate latent 
difference score modeling can establish the theoretical concepts, processes, and theories under 
investigation. Instead, statistical analysis is one approach to examining the process-outcome 
relations (Kenny, Korchmaros, & Bolger, 2003; McArdle & Nesselroade, 1994). Finally, 
although the study from which these data are derived was partly designed to facilitate these 
types of analyses (i.e., assessment strategy) and had significantly more power than previous 
studies, the study did not randomize across the theoretical concepts under consideration. As 
such, the results should be considered post-hoc in nature and appropriate caution should be 
used in their interpretation.   
Using bivariate latent difference score modeling, this study contributed to the 
understanding of processes underlying treatment in several ways. First, we replicated the 
importance of attribution variables consistently implicated in the process-outcome 
relationships in previous studies. Second, we expanded the list of process variables to 
agoraphobic avoidance and psychological flexibility. Third, we found clear evidence for the 
differentiation of meditational effects across outcomes (symptomatology vs. functioning). 
Finally, and most importantly, we found evidence that putative process variables are 
associated with changes in outcomes differently at different stages in the treatment. Increasing 
the time resolution under investigation allows for a better understanding of how processes 
unfold over time by overcoming a limitation of cross-sectional data. Namely, that they leave 
open the possibility that multiple constructs are relevant, but that they exert their effect at 
different points of time during therapy. The results in this study and similar studies have the 
potential to augment the effects of our current treatment and help therapists better deliver the 
treatments. The results point to specific processes at work and the timing of these processes. 
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If substantiated within and across disorders, results like these may help the sizeable minority 
of patients who do not respond (Hofmann & Smits, 2008) and/or potentially improve the 
long-term prospects of patients, which is currently unclear (Durham et al., 2005.) 
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Table 1: Distribution Outcome and Process Variables at Baseline and Post-assessment and Correlations Between Variables  
                        
            
   
Mean (SD) 
 
PAS CGI ACQ BSQ MI ASI AAQ-II 
                    
            Baseline 
  
Correlations between measures at Baseline 
            
 
Outcome variables 
         
  
PAS 27.8 (9.8) 
 
1 
      
  
CGI 4.54 (.90) 
 
.44 1 
     
 
Process variables 
         
  
ACQ 2.18 (.57) 
 
.37 .15 1 
    
  
BSQ 48.0 (12.4) 
 
.35 .12 .59 1 
   
  
MI 2.98 (.81) 
 
.55 .40 .17 .26 1 
  
  
ASI 31.4 (11.5) 
 
.40 .12 .53 .53 .22 1 
 
  
AAQ-II 45.3 (10.2) 
 
.19 .16 .36 .28 .14 .50 1 
            Post 
  
Correlations between measures at Post 
            
 
Outcome variables 
         
  
PAS 14.4 (9.3) 
 
1 
      
  
CGI 3.04 (1.25) 
 
.64 1 
     
 
Process variables 
         
  
ACQ 1.63 (.46) 
 
.58 .32 1 
    
  
BSQ 34.5 (11.9) 
 
.57 .36 .63 1 
   
  
MI 1.96 (.87) 
 
.56 .49 .43 .36 1 
  
  
ASI 16.6 (10.8) 
 
.65 .41 .63 .71 .37 1 
 
  
AAQ-II 52.3 (10.0) 
 
.48 .32 .48 .43 .28 .57 1 
                     
All correlations are significant at the 5% level; PAS = Panic Agoraphobia Scale; CGI = Clinical Global Impression; ACQ = 
Agoraphobic Cognitions Questionnaire ; BSQ = Bodily Sensations Questionnaire; ASI = Anxiety Sensitivity Inventory; MI = 
Mobility Inventory; AAQ-II = Acceptance and Action Questionnaire – II 
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 Table 2: Univariate LDS models for PAS, CGI, ACQ, BSQ, ASI, MI and AAQ-II 
                  
    PAS CGI ACQ BSQ ASI MI AAQ-II 
                  
Additive coefficients 
  
E[s] (Se); p 
value 27.8 (.6); p<.001 5.2 (.1); p<.001 2.2 (.03); p<.001 48.0 (.7); p<.001 31.3 (.7); p<.001 3.0 (.05); p<.001 45.3 (.6); p<.001 
  σ2(s) 67.85 .32 .25 102.10 122.48 .65 77.79 
                  
Proportional coefficients 
  β1 (Se); p value -.22 (.09); p=.021 -.46 (.15); p=.002 -.38 (.11); p=.001 -.12 (.13); p=.348 -* -.15 (.09); p=.102 -.25 (.12); p=.037 
  β2 (Se); p value -.43 (.11); p<.001 -.33 (.16); p=.043 -.56 (.12); p<.001 -.34 (.13); p=.009 -.82 (.06); p<.0011 -.37 (.10); p<.001 -.39 (.16); p=.015 
  β3 (Se); p value -.50 (.17); p=.004 -.50 (.21); p=.017 -.57 (.15); p<.001 -.20 (.15); p=.024 -.82 (.11); p<.001 -.39 (.13); p=.003 -.24 (.11); p=.029 
                  
Goodness of fit parameters 
  # 9 9 9 9 8 9 9 
  BIC 7459 3066 1105 7827 5670 1880 7371 
  Χ2 (df); p value 21.8 (5); p=.001 70.8 (5); p=.002 20.3 (5); p=.001 22.4 (5); p<.001 185.3 (3); p<.001 86.0 (5); p<.001 14.6 (5); p=.01 
  CFI .95 .86 .97 .96 .98 .87 .96 
  TLI .95 .86 .96 .95 .94 .84 .95 
  RMSEA .11 .14 .10 .11 .11 .08 .08 
  SRMR .06 .09 .05 .08 .04 .10 .09 
                  
PAS = Panic Agoraphobia Scale; CGI = Clinical Global Impression; ACQ = Agoraphobic Cognitions Questionnaire ; BSQ = Bodily Sensations 
Questionnaire; ASI = Anxiety Sensitivity Inventory; MI = Mobility Inventory; AAQ-II = Acceptance and Action Questionnaire – II; BIC = Bayesian 
information criterion, CFI = Comparative fit index, TLI = Tucker-Lewis index, RMSEA = Root mean square error of approximation; SRMR = 
standardized root mean square residual; # = number of model parameters; β1, β2 and β3 distinct time-varying proportional change coefficients; -* 
indicates that the parameter is not estimated due to missing ASI at intermediate assessment; 1 proportional change coefficient β2 refers to the interval 
baseline to post assessment 
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Table3: Bivariate LDS models for outcome PAS and process variables ACQ, BSQ, ASI, MI and AAQ-II 
              
              
    ACQ BSQ ASI MI AAQ-II 
              
              
Additive coefficients           
  E[αo] (Se); p value 27.81 (.56); p<.001 27.81 (.57); p<.001 27.78 (.57); p<.001 27.88 (.55); p<.001 27.77 (.57); p<.001 
  σ2(αo) 67.10 69.76 54.44 55.47 65.99 
  E[αp] (Se); p value 2.18 (.03); p<.001 48.00 (.71); p<.001 31.35 (.67); p<.001 2.98 (.05); p<.001 45.34 (.59); p<.001 
  σ2(αp) .24 103.00 98.22 .59 73.96 
              
Proportional coefficients           
  β1,PAS (Se); p value -.44 (.11); p<.001 -.85 (.11); p<.001 -* -1.24 (.21); p<.001 .02 (.22); p=.942 
  β2,PAS (Se); p value -.80 (.15); p<.001 -1.23 (.12); p<.001 -1.01 (.09); p<.001 -1.54 (.23); p<.001 -.12 (.25); p=.644 
  β3,PAS (Se); p value -1.20 (.22); p<.001 -1.80 (.23); p<.001 -1.40 (.17); p<.001 -1.67 (.26); p<.001 -.32 (.27); p=.227 
              
  β1,pv (Se); p value -.38 (.11); p=.001 -.18 (.10); p=.069 -* -.79 (.24); p=.001 .03 (.22); p=.891 
  β2,pv (Se); p value -.55 (.12); p<.001 -.41 (.11); p<.001 -.82 (.06); p<.0011 -.43 (.23); p=.067 .04 (.22); p=.865 
  β3,pv (Se); p value -.56 (.15); p<.001 -.28 (.14); p=.044 -.28 (.11); p<.001 .20 (.25); p=.413 -.11 (.23); p=.637 
              
Cross-lag coefficients           
  γ1,PAS_pv (Se); p value -** -** -* .13 (.02); p<.001 -.27 (.31); p=.386 
  γ2, PAS_pv (Se); p value -** -** -** .13 (.02); p<.001 -.04 (.33); p=.896 
  γ3, PAS_pv (Se); p value -** -** -** .13 (.02); p<.001 .08 (.36); p=.836 
              
  γ1, pv_PAS (Se); p value 15.20 (4.68); p=.001 .46 (.38); p=.665 -* 11.02 (2.31); p<.001 .10 (.22); p=.657 
  γ2, pv_PAS (Se); p value 17.18 (5.43); p=.002 .53 (.34); p=.706 .17 (.09); p=.0921 11.02 (2.31); p<.001 .13 (.27); p=.031 
  γ3, pv_PAS (Se); p value 22.94 (7.06); p=.001 .35 (.36); p=.685 .28 (.14); p=.022 11.02 (2.31); p<.001 .12 (.22); p=.583 
  
  
 
 
  
 table continues 
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Goodness of fit parameters           
  # 26 26 24 25 29 
  BIC 8339 15066 10919 9082 14753 
  Χ2 (df); p value 38.1 (18); p<.001 35.8 (18); p<.001 7.04 (4); p<.134 79.5 (19); p<.001 3.3 (15); p<.001 
  CFI .98 .98 1.00 .95 .98 
  TLI .97 .97 .98 .93 .97 
  RMSEA .06 .06 .05 .10 .06 
  SRMR .05 .06 .03 .06 .04 
              
PAS = Panic Agoraphobia Scale; ACQ = Agoraphobic Cognitions Questionnaire; BSQ = Bodily Sensations Questionnaire; ASI = Anxiety 
Sensitivity Inventory; MI = Mobility Inventory; AAQ-II = Acceptance and Action Questionnaire – II; BIC = Bayesian information criterion, CFI = 
Comparative fit index, TLI = Tucker-Lewis index, RMSEA = Root mean square error of approximation; SRMR = standardized root mean square 
residual; # = number of model parameters; β1, β2 and β3 distinct time-varying proportional change coefficients; γ1,PAS_pv, γ2,PAS_pv, γ3,PAS_pv distinct 
coupling coefficients for latent PAS predicting later change in process variable; γ1,pv_PAS, γ2, pv_PAS, γ3, pv_PAS distinct coupling coefficients for latent 
process variable predicting later change in PAS; -* indicates that the parameter is not estimated due to missing ASI at intermediate assessment; -** 
indicates that the parameter was not estimated because during the process of model building better model fit was obtained by excluding the 
parameter; 1 proportional change coefficient β2 refers to the interval baseline to post assessment 
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Table4: Bivariate LDS models for outcome CGI and process variables ACQ, BSQ, ASI, MI and AAQ-II 
              
              
    ACQ BSQ ASI MI AAQ-II 
              
              
Additive coefficients           
  E[αo] (Se); p value 5.17 (.05); p<.001 5.18 (.05); p<.001 5.17 (.05); p<.001 5.18 (.05); p<.001 5.17 (.05); p<.001 
  σ2(αo) .32 .02 1.15 .26 .31 
  E[αp] (Se); p value 2.18 (.03); p<.001 47.98 (.70); p<.001 31.37 (.66); p<.001 2.99 (.05); p<.001 45.33 (.59); p<.001 
  σ2(αp) .25 94.69 55.3 .56 74.05 
              
Proportional coefficients           
  β1,CGI (Se); p value -.50 (.23); p=.025 -2.84 (.94); p=.003 -* -1.47 (.37); p<.001 -1.98 (.65); p=.002 
  β2, CGI (Se); p value -.37 (.23); p=.109 -3.39 (1.14); p=.003 -1.36 (.16); p=.001 -1.63 (.37); p<.001 -2.14 (.68); p=.002 
  β3, CGI (Se); p value -.53 (.26); p=.037 -3.34 (1.16); p=.004 -1.52 (.17); p=.001 -1.52 (.40); p<.001 -1.44 (.54); p=.007 
              
  β1,pv (Se); p value -.43 (.15); p=.004 1.43 (.93); p=.123 -* -1.03 (.35); p=.003 -.48 (.34); p=.155 
  β2,pv (Se); p value -.59 (.15); p<.001 1.53 (1.04); p=.141 .00 (.13); p=.9821 -.80 (.36); p=.025 -.50 (.25); p=.047 
  β3,pv (Se); p value -.56 (.17); p=.001 1.73 (1.16); p=.136 -.12 (.10); p=.252 -.70 (.37); p=.058 -.89 (.40); p=.027 
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Cross-lag coefficients 
   γ1, CGI_pv (Se); p value .07 (.07); p=.308 -1.58 (6.17); p=.086 -* .96 (.24); p<.001 9.36 (3.27); p=.004 
  γ2, CGI_pv (Se); p value .07 (.07); p=.308 14.01 (7.50); p=.062 5.79 (1.63); p<.001 .96 (.24); p<.001 8.52 (3.35); p=.011 
  γ3, CGI_pv (Se); p value .07 (.07); p=.308 12.86 (7.63); p=.092 5.79 (1.63); p<.001 .96 (.24); p<.001 6.13 (2.79); p=.028 
              
  γ1, pv_CGI (Se); p value -.23 (.61); p=.710 .13 (.08); p=.109 -* 2.58 (.49); p<.001 .40 (.15); p=.008 
  γ2, pv_CGI (Se); p value -.23 (.61); p=.710 .11 (.08); p=.191 .06 (.02); p=.0011 2.58 (.49); p<.001 .43 (.17); p=.010 
  γ3, pv_CGI (Se); p value -.23 (.61); p=.710 .20 (.09); p=.031 .05 (.05); p=.684 2.58 (.49); p<.001 .47 (.19); p=.014 
              
Goodness of fit parameters           
  # 25 29 23 26 26 
  BIC 4125 10817 7967 4761 10385 
  Χ2 (df); p value 97.6 (19); p<.001 45.3 (15); p<.001 13.2 (4); p<.011 117.6 (18); p<.001 6.7 (18); p<.001 
  CFI .90 .96 .98 .90 .96 
  TLI .85 .92 .91 .85 .93 
  RMSEA .12 .08 .09 .14 .08 
  SRMR .18 .05 .04 .18 .09 
              
CGI = Clinical Global Impression; ACQ = Agoraphobic Cognitions Questionnaire; BSQ = Bodily Sensations Questionnaire; ASI = Anxiety 
Sensitivity Inventory; MI = Mobility Inventory; AAQ-II = Acceptance and Action Questionnaire – II; BIC = Bayesian information criterion, CFI = 
Comparative fit index, TLI = Tucker-Lewis index, RMSEA = Root mean square error of approximation; SRMR = standardized root mean square 
residual; # = number of model parameters; β1, β2 and β3 distinct time-varying proportional change coefficients; γ1,CGI_pv, γ2, CGI _pv, γ3, CGI _pv distinct 
coupling coefficients for latent PAS predicting later change in process variable; γ1,pv_ CGI, γ2, pv_ CGI, γ3, pv_ CGI distinct coupling coefficients for latent 
process variable predicting later change in PAS; -* indicates that the parameter is not estimated due to missing ASI at intermediate assessment; 1 
proportional change coefficient β2 refers to the interval baseline to post assessment 
 
 
